Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| First Hospital of China Medical University | OTHER |
| Zhongda Hospital | OTHER |
| Changzhou No.2 People's Hospital | OTHER |
| Tianjin Medical University General Hospital |
Not provided
Not provided
Not provided
Not provided
Liver abscess is a rare but serious complication of hepatocellular carcinoma after TACE, with an incidence of less than 1% reported in previous literature. Studies have shown that history of biliary tract disease, tumor size, embolization materials and embolization endpoint selection may be related to the occurrence of abscess. In recent years, with the wide application of targeted and immune drugs, there have been reports of multiple cases of liver abscess after single target immunotherapy for liver cancer, and there have also been studies showing that TACE combined with targeted immunotherapy can significantly increase the degree of liquefaction necrosis and increase the risk of liver abscess. However, these studies are single-center reports with small sample size and low level of evidence. Therefore, it is of great clinical significance to explore the risk factors of liver abscess after TACE and build a prediction model by using multi-center and large sample data. The formation of liver abscess after TACE means a large range of tissue liquefaction necrosis. There are reports of high incidence of early recurrence and metastasis of liquefaction necrosis. Some studies also show that tumor necrosis is more complete when liver abscess is combined with complete remission. In previous studies, ORR in patients with liver cancer complicated with liver abscess ranged from 18.75%-100%, with significant differences in reports from different centers. The effect of specific abscess formation on TACE efficacy of liver cancer remains to be determined. Therefore, the second research focus of this project is to explore the effect of liver abscess formation after TACE on prognosis of liver cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with liver abscess formation after TACE for HCC | |||
| Patients without liver abscess after TACE with HCC |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Whether combined targeted therapy was a risk factor for liver abscess formation after TACE. | The targeted treatment of patients with and without liver abscess after TACE was collected, and conclusion was drawn by univariate and multivariate analysis. | one year |
| Whether combined immunotherapy was a risk factor for liver abscess formation after TACE. | The immunotherapy of patients with and without liver abscess after TACE was collected, and conclusion was drawn by univariate and multivariate analysis. | one year |
| Measure | Description | Time Frame |
|---|---|---|
| Survival time of patients with liver abscess formation after TACE. | Patients with liver abscess formation after TACE were followed up regularly to determine their survival status. | one year |
Not provided
Inclusion Criteria:
Case group inclusion criteria:
Condition 1: CT images show typically low-density lesions with or without air and fluid levels
Condition 2:
Control group inclusion criteria
Patients with HCC without liver abscess who underwent TACE in the same center within the week of treatment in the case group.
-
Exclusion Criteria:
Not provided
Not provided
Not provided
HCC patients from hospital interventional wards receiving TACE
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zhihui Chang | Contact | +86-18940258437 | Changzh@sj-hospital.org |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER |
| Huazhong University of Science and Technology | OTHER |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| D008100 | Liver Abscess |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |
| D018784 | Abdominal Abscess |
| D000038 | Abscess |
| D013492 | Suppuration |
| D007239 | Infections |
Not provided
Not provided